Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Biodesix (BDSX) EBITDA: 2019-2024

Historic EBITDA for Biodesix (BDSX) over the last 6 years, with Dec 2024 value amounting to -$34.5 million.

  • Biodesix's EBITDA rose 17.93% to -$7.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$32.6 million, marking a year-over-year increase of 6.23%. This contributed to the annual value of -$34.5 million for FY2024, which is 16.55% up from last year.
  • Per Biodesix's latest filing, its EBITDA stood at -$34.5 million for FY2024, which was up 16.55% from -$41.3 million recorded in FY2023.
  • Biodesix's 5-year EBITDA high stood at -$22.9 million for FY2020, and its period low was -$50.6 million during FY2022.
  • Moreover, its 3-year median value for EBITDA was -$41.3 million (2023), whereas its average is -$42.1 million.
  • In the last 5 years, Biodesix's EBITDA tumbled by 78.51% in 2021 and then grew by 18.28% in 2023.
  • Biodesix's EBITDA (Yearly) stood at -$22.9 million in 2020, then slumped by 78.51% to -$40.9 million in 2021, then fell by 23.56% to -$50.6 million in 2022, then grew by 18.28% to -$41.3 million in 2023, then rose by 16.55% to -$34.5 million in 2024.